GlassScriptPhysician profile
Phillip N Fyman
NPI 1528050051
$3,674.70
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,612 · 2020: $1,010 · 2021: $1,053.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $467.07 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $383.56 | 2020-2021 | |
| Allergan, INC. | $282.89 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $278.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.50 | 2019-2021 | |
| Daiichi Sankyo INC. | $228.35 | 2019 | |
| Assertio Therapeutics, INC. | $154.81 | 2019-2020 | |
| Eisai INC. | $153.91 | 2020-2021 | |
| Abbvie INC. | $124.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $107.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $98.85 | 2019-2021 | |
| Sentynl Therapeutics, INC. | $95.78 | 2019-2020 | |
| Almatica Pharma LLC | $94.62 | 2021 | |
| Arbor Pharmaceuticals, INC. | $90.90 | 2019-2021 | |
| Nevro Corp. | $88.98 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.26 | 2019-2020 | |
| Redhill Biopharma INC. | $72.72 | 2020-2021 | |
| Horizon Therapeutics Plc | $63.72 | 2020 | |
| Shionogi INC | $55.25 | 2019 | |
| Vertical Pharmaceuticals, LLC | $54.90 | 2019 | |
| Boston Scientific Corporation | $46.56 | 2020-2021 | |
| Forte Bio-Pharma LLC | $45.36 | 2021 | |
| Biodelivery Sciences International, INC. | $45.08 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.04 | 2019-2020 | |
| Lilly USA, LLC | $36.43 | 2019 | |
| Grt US Holding, INC. | $36.16 | 2021 | |
| Indivior INC. | $30.37 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $22.26 | 2020 | |
| Amgen INC. | $17.81 | 2019 | |
| Si-Bone, INC. | $17.50 | 2019 | |
| Zyla Life Sciences, INC. | $16.12 | 2020 | |
| Orexo US, INC. | $14.44 | 2019 | |
| Abbott Laboratories | $14.20 | 2020 | |
| Virtus Pharmaceuticals LLC | $13.36 | 2020 | |
| Currax Pharmaceuticals LLC | $12.66 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.97 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Fyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.